Circulating MicroRNA-4739 May Be a Potential Biomarker of Critical Limb Ischemia in Patients with Diabetes

Table 1

General characteristic of the study subjects for validation study.

	CLI	Non - CLI	P
Case, n	26	30	--
Age, years	64.54±2.83	61.50 (57.50-69.25)	0.806
T2D Duration, years	15.85±1.48	9.00 (8.00-14.25)	0.003
Women, %	13, (50.00)	15, (50.00)	1.000
Hyperlipidemia, %	10, (38.46)	10, (33.33)	0.690
Hypertension, %	15, (57.69)	9, (30.00)	0.037
Smoking, %	15, (57.69)	8, (26.67)	0.019
ABI	0.58±0.04	1.11±0.01	0.000
BMI, kg/m^2	24.20 (23.30-26.23)	25.54±0.53	0.528
CAD, %	7, (26.92)	8, (26.67)	0.983
Statin use, %	5, (19.23)	4, (13.33)	0.549
Antihypertensive treatment use, %	7, (26.92)	5, (16.67)	0.351
Metformin use, %	21, (80.77)	23, (76.67)	0.709
FPG, mmol/L	9.74 (8.82-14.40)	7.22 (6.13-8.90)	0.001
HbA1c, %	8.95 (7.88-9.63)	6.90 (6.50-9.05)	0.002
HDL-C, mmol/L	1.08±0.05	1.16 (0.89-1.31)	0.274
LDL-C, mmol/L	2.61±0.18	2.64±0.15	0.920
TG, mmol/L	1.50 (1.06-1.88)	1.29 (0.92-1.86)	0.862
TC, mmol/L	2.86 (2.59-4.03)	4.31±0.18	0.012
Apo A, g/L	1.16 (1.02-0.28)	1.14 (1.06-1.30)	0.172
Apo B, g/L	0.92±0.04	0.85±0.04	0.286
Cr, μmol/L	77.50 (58.00-107.45)	65.70 (55.75-72.25)	0.046
BUN, mmol/L	5.61 (4.60-7.60)	6.15±0.41	0.366
UA, mmol/L	324.60±13.53	324.29±19.39	0.899
hsCRP, mg/dL	0.36 (0.19-1.37)	0.65 (0.27-2.53)	0.405

ABI, Ankle brachial index; BMI, body mass index; CAD, coronary artery disease; FPG, fasting plasma glucose; HbA1c, glycosylated hemoglobin; HDL-C, high density lipoprotein cholesterol; LDL-C, low density lipoprotein cholesterol; TG, triglyceride; TC, total cholesterol; Apo A, Apolipoprotein A; Apo B, Apolipoprotein B; Cr, serum creatinine; BUN, blood urea nitrogen; UA, uric acid; hsCRP, high-sensitivity C-reactive protein. Data is expressed as mean±SEM, median (interquartile range), or percentage. Significant values are marked in italic. Continuous variables were compared by the Fisher-Pitman Permutation test, and categorical variables were compared by Fisher’s exact test in the miRNA array cohort; however, the validation cohort was analyzed using ) test or ) Mann-Whitney U test, and the others were analyzed using t-tests.